The Aryl Ring Or Aryl Ring System And Amino Nitrogen Are Bonded Directly To The Same Acylic Carbon, Which Carbon Additionally Has Only Hydrogen Or Acyclic Hydrocarbyl Substituents Bonded Directly Thereto Patents (Class 514/655)
-
Publication number: 20110104235Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.Type: ApplicationFiled: January 6, 2011Publication date: May 5, 2011Inventors: Frank Kochinke, Corinne Bright
-
Publication number: 20110097407Abstract: Disclosed is a water-based adhesive skin patch which has excellent storage stability, can achieve excellent accumulation of butenafine hydrochloride contained therein on a patched area such as the skin and a nail, and has a high therapeutic effect. Specifically disclosed is a water-based adhesive skin patch containing butenafine hydrochloride, which is characterized by containing butenafine hydrochloride, glycol salicylate and propylene glycol in a water-containing gel ointment. Specifically, butenafine hydrochloride is dissolved in a mixed solution of glycol salicylate and propylene glycol, and the resulting solution is dispersed in a water-containing gel. Particularly, the mixing ratio of glycol salicylate to propylene glycol is 1:2 to 1:30.Type: ApplicationFiled: March 24, 2009Publication date: April 28, 2011Applicant: TEIKOKU SEIYAKU CO., LTD.Inventors: Takashi Kamakura, Takefumi Hoshikawa, Yukiko Inamoto, Kayo Tanigawa
-
Publication number: 20110086071Abstract: This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration.Type: ApplicationFiled: December 14, 2010Publication date: April 14, 2011Inventors: Jean-Daniel Bonny, Andreas Carl Eugster, Patrice Guitard, Stefan Hirsch
-
Publication number: 20110070270Abstract: An immunostimulating agent, which can stimulate immunity effectively, is described. The immunostimulating agent contains an active ingredient including a calcium receptor activator such as ?-Glu-X-Gly [wherein X represents an amino acid or a derivative thereof other than Cys], ?-Glu-Val-Y [wherein Y represents an amino acid or a derivative thereof], ?-Glu-Ala, ?-Glu-Gly, ?-Glu-Met, ?-Glu-Thr, ?-Glu-Val, ?-Glu-Orn, Asp-Gly, Cys-Gly, Cys-Met, Glu-Cys, Gly-Cys, Leu-Asp, ?-Glu-Met(O), ?-Glu-?-Glu-Val, ?-Glu-Val-NH2, ?-Glu-Val-ol, ?-Glu-Ser, ?-Glu-Tau, ?-Glu-Cys(S-Me)(O), ?-Glu-Leu, ?-Glu-Ile, ?-Glu-t-Leu, ?-Glu-Cys(S-Me), a cation having a valency of 2 or more, protamine, polylysine, spermine, spermidine, putrescine, cinacalcet, a cinacalcet analogue compound, and a salt of any one of the aforementioned components.Type: ApplicationFiled: October 6, 2010Publication date: March 24, 2011Inventors: Tomohiro Kodera, Yuzuru Eto, Yoshinori Mine
-
Publication number: 20110067123Abstract: This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.Type: ApplicationFiled: February 18, 2009Publication date: March 17, 2011Inventors: Julie Andersen, Jyothi Kumar Mallajosyula
-
Publication number: 20110065760Abstract: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and S(O2)—NR14—, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y.Type: ApplicationFiled: November 23, 2009Publication date: March 17, 2011Applicant: Jerini AGInventors: Jochen KNOLLE, Mike Schutkowski, Gerd Hummel, Thomas Tradler, Laurence Jobron, Claudia Christner, Dirk Scharn, Roland Stragies, Christoph Gibson, Frank Osterkamp
-
Publication number: 20110015240Abstract: The invention provides a thiazole derivative useful as a VAP-1 inhibitor, as well as a pharmaceutical agent for the prophylaxis or treatment of VAP-1 associated diseases and the like, a method of inhibiting VAP-1 in a subject, and a method for the prophylaxis or treatment of VAP-1 associated disease in a subject. The thiazole derivative is a compound represented by the formula (I): R1—NH—X—Y—Z wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 30, 2009Publication date: January 20, 2011Applicant: R-TECH UENO, LTD.Inventors: Tatsuya Matsukawa, Kazuhiro Masuzaki, Yosuke Kawai, Akiko Kawasaki, Akiko Akasaka, Makoto Takewaki
-
Publication number: 20100330176Abstract: The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity.Type: ApplicationFiled: August 23, 2010Publication date: December 30, 2010Applicant: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KGInventors: Anke ESPERESTER, Uwe PSCHORN, Jean-Michel VIX
-
Publication number: 20100324064Abstract: The present invention relates to novel analogs of choline and methods of use or treatment of neurodegenerative disorders and/or conditions such as Parkinson's disease, Huntington disease, Alzheimer's disease and related disorders such as amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease (mad cow disease), dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke. The present compounds are effective to treat any neurological condition where acetylcholine transmission neurons and their target cells are affected.Type: ApplicationFiled: July 22, 2010Publication date: December 23, 2010Applicants: Medical College of Georgia Research Institute, Universtiy of Georgia Research FoundationInventors: Jerry J. BUCCAFUSCO, Alvin V. Terry, J. Warren Beach, Rammamohanna R. Jonnala
-
Patent number: 7851654Abstract: Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step with hydroxybenzaldehide under the presence of an appropriate catalyst. The chalcone derivative of formula 1 in accordance with the present invention having strong enzyme inhibitory activities for glycosidase can be effectively used in preventing and treating various diseases induced by glycosidase, and the chalcone derivative of the invention having tyrosinase and melanin synthesis inhibitory activities can be effectively used as a skin-whitening compound.Type: GrantFiled: April 3, 2006Date of Patent: December 14, 2010Assignee: Industry-Academic Cooperation Foundation Gyeongsang National UniversityInventors: Ki Hun Park, Jin Hyo Kim, Woo Duck Seo, Young Bae Ryu, Hyung Won Ryu, Woo Song Lee, Sang Wan Gal
-
Publication number: 20100305081Abstract: A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided.Type: ApplicationFiled: August 13, 2010Publication date: December 2, 2010Applicant: MediQuest Therapeutics, Inc.Inventor: Frederick J. Dechow
-
Patent number: 7842729Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: June 3, 2005Date of Patent: November 30, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Sequella, Inc.Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
-
Publication number: 20100298328Abstract: 1-Heterocyclylamino-2-hydroxy-3-amino-?-arylalkanes of formula (I) and the salts thereof have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.Type: ApplicationFiled: March 30, 2007Publication date: November 25, 2010Inventors: John J. Baldwin, David A. Claremon, Lawrence W. Dillard, Alexey V. Ishchenko, Jing Yuan, Zhenrong Xu, Gerard McGeehan, Wenguang Zeng
-
Publication number: 20100292195Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: ApplicationFiled: February 13, 2008Publication date: November 18, 2010Applicant: QLT USA, INC.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Patent number: 7834062Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.Type: GrantFiled: August 13, 2009Date of Patent: November 16, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt
-
Publication number: 20100278890Abstract: Disclosed are compositions and methods related to powder and granular concentrate pesticide formulations. As disclosed, suspo-emulsions comprising pesticide actives may be prepared using a high purity, high molecular weight lignosulfonate as a stabilizer. The resulting suspo-emulsions may then be dried to obtain a powder or granular concentrate where the high molecular weight lignosulfonate acts as a solid matrix for the pesticide actives. The powder or granular concentrate formulations thus formed have high loading rates, good storage properties and are easily reconstituted when added to water.Type: ApplicationFiled: April 29, 2010Publication date: November 4, 2010Applicant: LIGNOTECH USA, INC.Inventor: Thomas S. Winowiski
-
Patent number: 7820720Abstract: The present invention relates to topical antifungal formulations terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.Type: GrantFiled: January 19, 2010Date of Patent: October 26, 2010Assignee: TDT LimitedInventors: Gregor Cevc, Ulrich Vierl
-
Publication number: 20100267678Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20100260750Abstract: Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.Type: ApplicationFiled: June 21, 2007Publication date: October 14, 2010Applicant: Ramot At Tel Aviv University LtdInventors: Moshe Rehavi, David Gurwitz
-
Publication number: 20100256122Abstract: Certain substituted butyl and butynyl benzyl amine compounds are histamine H3 receptor and/or serotonin transporter modulators useful in the treatment of histamine H3 receptor- and/or serotonin-mediated diseases.Type: ApplicationFiled: June 22, 2010Publication date: October 7, 2010Inventors: John M. Keith, Michael A. Letavic, Emily M. Stocking
-
Publication number: 20100247439Abstract: Provided are dendritic nano-antioxidant compounds according to Formula I, which may further comprise active agents covalently or non-covalently attached. Further provided are compositions comprising the disclosed compounds. Also disclosed are cosmetic compositions and dietary supplements comprising the compounds according to Formula I. The invention additionally provides methods of reducing free radicals or oxidative stress in a cell, a method of treating a subject, and a method of treating a condition comprising administering the compounds according to Formula I.Type: ApplicationFiled: March 29, 2010Publication date: September 30, 2010Inventor: Choon Young Lee
-
Publication number: 20100240747Abstract: Disclosed herein are motuporamine mimic agents and methods of making and using same. Particularly exemplified are motuporamine mimic agents comprising cytotoxic activity and/or anti-metaplastic activity.Type: ApplicationFiled: June 1, 2010Publication date: September 23, 2010Inventor: Otto Phanstiel
-
Publication number: 20100215775Abstract: The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff formation, as well as to cosmetic and/or dermatological preparations comprising C10-C14-alkane-1,2-diols.Type: ApplicationFiled: October 12, 2007Publication date: August 26, 2010Applicant: SYMRISE GmbH & Co. KGInventors: Gerhard Schmaus, Sabine Lange
-
Publication number: 20100216830Abstract: The present invention relates to a formulation comprising an endothermic cooling agent selected from the group consisting of xylitol, sorbitol, mannitol and erythritol having a heat of enthalpy between ?10 cal/g and ?100 cal/g, and one or more active agents wherein the endothermic agent is present in the formulation at an amount less than 10% w/w.Type: ApplicationFiled: October 17, 2008Publication date: August 26, 2010Applicant: Reckitt Benckkiser Healthcare (UK) LimtedInventors: Kingsley Iyoha, Neil Campbell Muir, Robert Rhoades, Alden Rodwell, David Michael Thurgood
-
Publication number: 20100172916Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: November 9, 2009Publication date: July 8, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Craig Hodulik, Soon Woo
-
Publication number: 20100173904Abstract: A tropical composition is provided. The topical composition can be prepared by diluting a topical composition precursor with water and adding additional components, if desired. The topical composition precursor can be prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups wherein the alkylene groups contain at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic groups and/or repeating hydroxyl groups. A topical composition precursor and methods for manufacturing and using a topical composition are provided by the invention.Type: ApplicationFiled: March 8, 2010Publication date: July 8, 2010Applicant: Skinvisible Pharmaceuticals, Inc.Inventors: James A. Roszell, Bruce Jezior
-
Publication number: 20100172993Abstract: The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.Type: ApplicationFiled: August 10, 2007Publication date: July 8, 2010Inventors: Amarjit Singh, Sarabjit Singh, Paramjit Singh, Rajesh Jain
-
Publication number: 20100168233Abstract: The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present.Type: ApplicationFiled: February 20, 2008Publication date: July 1, 2010Applicant: POWER PAPER LTDInventors: Dalia Jayes, Boaz Nitzan, Michal Royz, David Barak, Orit Sholto, Rachel Mosckovitz-Silversmith, Shirly Ben-Yaakov Duady, Doron Firedman
-
Publication number: 20100168247Abstract: The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith.Type: ApplicationFiled: March 12, 2010Publication date: July 1, 2010Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD.Inventors: Ilan Zalit, Uri Zadok
-
Publication number: 20100160273Abstract: A topical sustained release delivery system for delivery of antifungal agents to the finger or toenails achieving high penetration through the nails by combining the antifungal agent with a keratolytic agent and a humectant. The pharmaceutical sustained release topical preparation is provided in a varnish or spray form for treating the nail and surrounding tissues, where the active ingredient is an antifungal agent, a keratolytic agent or combination thereof. The composition may further include an antibacterial, an antiviral, an antipsoriatic agents, or combinations thereof.Type: ApplicationFiled: January 5, 2010Publication date: June 24, 2010Applicant: TARO PHARMACEUTICAL INDUSTRIES LTD.Inventors: MICHAEL FRIEDMAN, DANIELLA LICHT, AVRAHAM YACOBI
-
Publication number: 20100143287Abstract: The present invention relates to new trifluoromethylphenyl modulators of calcium-sensing receptor, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 8, 2009Publication date: June 10, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventor: Thomas G. Gant
-
Publication number: 20100137333Abstract: An antifungal composition is provided according to the present invention. The antifungal composition comprises an effective amount of an antifungal component to provide antifungal properties to skin tissue, an effective amount of a skin bonding polymer component to provide a sustained release of the antifungal component over a prolonged period of time after application of the antifungal treatment composition to skin tissue, and water. A method for using the antifungal composition is provided.Type: ApplicationFiled: October 19, 2007Publication date: June 3, 2010Inventor: James A. Roszell
-
Publication number: 20100129447Abstract: A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.Type: ApplicationFiled: April 23, 2008Publication date: May 27, 2010Inventors: Corey Jay Bloom, Marshall David Crew, Daniel Tod Smithey, Warren Kenyon Miller, Michael Mark Morgen
-
Patent number: 7714170Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, use in the reduction of A? peptide in vivo, use in modulating APP processing, and use in modulating the activity of APP secretase.Type: GrantFiled: December 8, 2008Date of Patent: May 11, 2010Assignee: Proteotech, Inc.Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
-
Publication number: 20100113607Abstract: A method for the topical treatment of nail diseases, e.g. onychomycosis, after preparation of the infected nail with a laser beam.Type: ApplicationFiled: December 11, 2009Publication date: May 6, 2010Inventor: Alfredo Emilio Bruno-Raimondi
-
Publication number: 20100104633Abstract: The present invention relates to topical antifungal formulations terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.Type: ApplicationFiled: January 19, 2010Publication date: April 29, 2010Inventors: Gregor Cevc, Ulrich Vierl
-
Publication number: 20100105733Abstract: The present invention is directed toward methods for treating vasomotor symptoms, (e.g., hot flashes and night sweats) in a patient in need thereof comprising administering a SERM as described herein.Type: ApplicationFiled: June 22, 2007Publication date: April 29, 2010Inventors: C. Richard Lyttle, Bart Henderson, Gary Hattersley
-
Patent number: 7700658Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.Type: GrantFiled: January 29, 2008Date of Patent: April 20, 2010Assignee: Pfizer Inc.Inventors: James A. Sikorsky, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
-
Publication number: 20100093677Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, Synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: ApplicationFiled: October 9, 2009Publication date: April 15, 2010Inventor: Erica Brook Goodhew
-
Publication number: 20100087545Abstract: Process for the preparation of pure allylamine pharmaceutical terbinafine of formula I in free base form or acid addition salt form, by distilling crude terbinafine base, preferably by short path distillation, e.g. at a temperature above 100° C. and reduced pressure, e.g. 0.2 mbar, and recovering the purified product in free base or acid addition salt form. The process is indicated for use in removal of metal or non-metal contaminants, optionally together with salt formation under simultaneous precipitation of pure trans isomer. Detection of non-metal contaminants such as substance A of formula preferably is effected by RP HPLC analysis with UV detection.Type: ApplicationFiled: January 16, 2009Publication date: April 8, 2010Inventors: Ulrich Beutler, Peter Funfschilling, Gerhard Penn, Alfons Roth
-
Publication number: 20100086504Abstract: The present invention relates to topical antifungal formulations comprising one or more antifungal (e.g., terbinafine), a lipid and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.Type: ApplicationFiled: July 23, 2009Publication date: April 8, 2010Inventors: Gregor Cevc, Ulrich Vierl
-
Publication number: 20100068307Abstract: A foaming gelled composition in the form of a stable oil-in-water microemulsion comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system comprising:—at least one ethoxylated nonionic surfactant;—at least one cosurfactant for stabilizing the ethoxylated nonionic surfactant;—at least one nonethoxylated hydrophilic nonionic surfactant;—at least one foaming agent chosen from the group of anionic surfactants.Type: ApplicationFiled: January 25, 2008Publication date: March 18, 2010Applicant: PIERRE FABRE DERMO-COSMETIQUEInventor: Francoise Nielloud
-
Publication number: 20100048724Abstract: Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly using a solid, semi-solid, or flowable carrier. The carrier can be in the form of a semi-solid into which the user digs and scrapes the nail, a solid carrier can be inserted directly under the nail in contact with the nail bed, or a flowable composition can be injected in contact with the nail bed.Type: ApplicationFiled: October 27, 2009Publication date: February 25, 2010Inventors: Jay E. Birnbaum, Keith A. Johnson
-
Publication number: 20100009970Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.Type: ApplicationFiled: March 18, 2009Publication date: January 14, 2010Applicant: Combinatorx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens, Christina Mawhinney, Todd W. Chappell, Alexander T. Brown, Michael G. Frank, Michael A. Foley, Ralf Altmeyer, Yu Chen
-
Publication number: 20090324696Abstract: The present subject matter provides a nail patch comprising a backing layer and a pressure-sensitive adhesive layer disposed on at least one side of the backing layer, wherein the pressure-sensitive adhesive layer comprises a pressure-sensitive adhesive base, terbinafine and/or a pharmacologically acceptable salt thereof, and sodium acetate and/or sorbitan monolaurate as a solubilizer.Type: ApplicationFiled: July 6, 2007Publication date: December 31, 2009Inventors: Arata Toshimitsu, Naoko Matsuda, Toshihiro Kogure, Kazuya Ishida
-
Patent number: 7632843Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effective amount of 9,10-didehydro-N-methyl-N-(2-propy-nyl)-6-methyl-8?-aminomethylergo-line in the form of free base or in the form of pharmaceutically acceptable addition salt, in particular the bimaleate salt, as well as pharmaceutical compositions containing said compound. In literature, the compound is also known under code LEK-8829. More particularly, present invention relates to a novel method of treatment for reduction of abstinence symptoms after cocaine withdrawal and for suppression the symptoms of craving for cocaine withdrawal and for suppression the symptoms of craving for cocaine reinforcement, and to the use of said active substance for the preparation of the pharmaceutical composition for the treatment of cocaine addiction.Type: GrantFiled: December 11, 2003Date of Patent: December 15, 2009Assignee: Lek Pharmaceuticals d.d.Inventors: Igor Krisch, Marko Zivin, Natasa Milivojevic, Rudolf Rucman, Breda Bole-Vunduk, Uros Urleb
-
Patent number: 7601876Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.Type: GrantFiled: March 5, 2007Date of Patent: October 13, 2009Assignee: Proteotech, Inc.Inventors: Alan D. Snow, Beth P. Nguyen, Gerardo M. Castillo, Virginia J. Sanders, Thomas P. Lake, Lesley Larsen, Rex T. Weavers, Stephen D. Lorimer, David S. Larsen, David L. Coffen, Charlotte Coffen, legal representative
-
Publication number: 20090252694Abstract: Disclosed relates to a novel chalcone derivative, pharmaceutically acceptable salt thereof, a method for preparing the same and uses thereof, the chalcone derivative being readily obtained through the steps of: reacting aminoacetophenone with sulfonylchloride under the presence of an appropriate salt; and reacting the compound prepared in the above step with hydroxybenzaldehide under the presence of an appropriate catalyst. The chalcone derivative of formula 1 in accordance with the present invention having strong enzyme inhibitory activities for glycosidase can be effectively used in preventing and treating various diseases induced by glycosidase, and the chalcone derivative of the invention having tyrosinase and melanin synthesis inhibitory activities can be effectively used as a skin-whitening compound.Type: ApplicationFiled: April 3, 2006Publication date: October 8, 2009Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIYInventors: Ki Hun Park, Jin Hyo Kim, Woo Duck Seo, Young Bae Ryu, Hyung Won Ryu, Woo Song Lee, Sang Wan Gal
-
Publication number: 20090247529Abstract: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided.Type: ApplicationFiled: June 14, 2007Publication date: October 1, 2009Applicants: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Ake Lindahl, Birgitta Svensson, Anna Holmberg, Johan Engblom
-
Patent number: 7589127Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.Type: GrantFiled: June 20, 2003Date of Patent: September 15, 2009Assignee: Merck & Co., Inc.Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt